Medicenna to present MDNA11 trial data at SITC 2026 meeting
Tweet Send to a Friend
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF) announced that topline data from its Phase 1/2 ABILITY-1 clinical trial of MDNA11 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




